Traded Dec 29, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Dec 1, 2025 · Filed Dec 3, 2025
United Therapeutics's PRESIDENT AND COO sold $113K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$113,120
Shares × reported transaction price
33 days after results of Oct 29, 2025, 86 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.8% | +0.5% | +0.3% |
| 30 days | +3.3% | −0.1% | +3.4% |
| 90 days | +3.7% | −0.5% | +4.2% |
| 180 days | +13.2% | +10.9% | +2.3% |
Past results only. Not a forecast.
Traded Dec 29, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Michael Benkowitz (PRESIDENT AND COO) sold ~$7.35M of United Therapeutics
Scheduled in advanceTraded Dec 29, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.